Vaccines targeting different stages of malaria parasites
mRNA-LNP vaccines targeting multiple stages and multiple species of human malaria parasite
This study is working on new vaccines that can help protect against malaria by targeting different stages of the malaria parasites, which could lead to better prevention and less spread of the disease for people at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11048034 on NIH RePORTER |
What this research studies
This research focuses on developing innovative vaccines that target multiple life stages of malaria parasites, specifically Plasmodium falciparum and P. vivax. By creating combination vaccines that address sporozoites and gametocytes, the project aims to enhance immune protection and reduce malaria transmission. The approach includes utilizing specific proteins from the malaria parasites to stimulate a robust immune response. Patients may benefit from these vaccines as they could lead to more effective prevention strategies against malaria.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living in malaria-endemic regions, particularly in Asia, Africa, and Central and South America.
Not a fit: Patients who do not reside in malaria-endemic areas or those who are not at risk of malaria infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective malaria vaccines that significantly reduce infection rates and transmission.
How similar studies have performed: Previous research has shown promise with malaria vaccines targeting specific life stages, indicating potential for success with this novel approach.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Kumar, Nirbhay — George Washington University
- Study coordinator: Kumar, Nirbhay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.